Verona pharma, a biopharmaceutical company based in the UK, announced positive results from a QT study designed to evaluate the effects of its new drug–ensifentrine– an inhaled small molecule, long-acting, dual phosphodiesterase (PDE) 3/4 inhibitor, for the treatment of asthma, chronic obstructive pulmonary disease (COPD)and cystic fibrosis, on cardiac conduction in healthy individuals. The US FDA requires a TQT study to support most New Drug Applications for potential new medications and this trial results will support the submission of the drug as COPD treatment medicine. The researchers at the company said that the trial was a randomized, double-blind and crossover study in 32 volunteers to evaluate the effect of therapeutic and supratherapeutic doses of nebulized ensifentrine on measures of cardiac conduction compared with placebo. The company said that they would continue to evaluate the rug in phase 3 trials, the results of which are expected to be out by 2022.